Promoting research partnerships 

to improve veterans’ health

NAVREF News Center

<< First  < Prev   1   2   3   4   5   ...   Next >  Last >> 
  • 18 Jul 2018 5:10 PM | Hawk Tran (Administrator)

    FY18 BCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on Grants.gov. 

     

    As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA), J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

     

    Applications submitted to the FY18 BCRP must address one or more of the following overarching challenges:

    • ·         Prevent breast cancer (primary prevention)
    • ·         Identify determinants of breast cancer initiation, risk, or susceptibility
    • ·         Distinguish deadly from non-deadly breast cancers
    • ·         Conquer the problems of over diagnosis and overtreatment
    • ·         Identify what drives breast cancer growth; determine how to stop it
    • ·         Identify why some breast cancers become metastatic
    • ·         Determine why/how breast cancer cells lie dormant for years and then re-emerge; determine how to prevent lethal recurrence
    • ·         Revolutionize treatment regimens by replacing them with ones that are more effective, less toxic, and impact survival
    • ·         Eliminate the mortality associated with metastatic breast cancer

     

    http://cdmrp.army.mil/funding/bcrp

     

    Breakthrough Award Level 1 & 2– Letter of Intent due November 1, 2018

    • ·         Investigators at all academic levels (or equivalent) are eligible to be names as Principal Investigator (PI).
    • ·         Applications from senior postdoctoral fellows who do not meet the eligibility requirements of the Breakthrough Fellowship Award are encouraged underfunding Level 1 and 2.
    • ·         Each investigator may be named on only one Funding Level 1 application and Funding Level 2 application as a PI or Initiating PI.
    • ·         Supports promising research that has the potential to lead to or make breakthroughs in breast cancer.
    • ·         Potential impact of the research may be near-term or long-term, but it must be significant and go beyond an incremental advancement.
    • ·         Partnering PI Option allows two PIs, termed Initiating and Partnering PIs, to collaborate on a single application.
    • ·         When submitting the pre-application, it is the responsibility of the applicant to select the funding level that is most appropriate for the research proposed.  The funding level should be selected based on the scope of the research project, rather than the amount of the budget.
    • ·         There are no limitations on the number of applications for which an investigator may be named as a
    • ·         Partnering PI.  However, submission of applications with the same Partnering PI on multiple applications is discouraged unless they are clearly unique, meaningful collaborations addressing distinct research questions.
    • ·         Additional funds are available for applications submitted under the Partnering PI Option.
    • ·         Clinical trials are not allowed.
    • ·         Submission of a Letter of Intent is required prior to full application submission.
    • ·         Funding Level 1:
    • ·         Maximum funding of $375,000 for direct costs (plus indirect costs)
    • ·         Maximum period of performance is 3 years
    • ·         Funding Level 1 – Partnering PI Option:
    • ·         Maximum funding of $600,000 for direct costs (plus indirect costs)
    • ·         Maximum period of performance is 3 years
    • ·         Funding Level 2:
    • ·         Maximum funding of $750,000 for direct costs (plus indirect costs)
    • ·         Maximum period of performance is 3 years
    • ·         Funding Level 2 – Partnering PI Option:
    • ·         Maximum funding of $1M for direct costs (plus indirect costs)
    • ·         Maximum period of performance is 3 years

     

    Breakthrough Award Level 3 & 4– Preproposal due September 14, 2018

    • ·         Independent investigators at all academic levels (or equivalent) are eligible to be names as PI.
    • ·         Each investigator may submit one Funding Level 3 pre-application and on Funding Level 4 pre-application as a PI or Initiating PI.
    • ·         Supports promising research that has the potential to lead to or make breakthroughs in breast cancer.
    • ·         Potential impact of the research may be near-terms or long-term, but it must be significant and go beyond an incremental advancement.
    • ·         Partnering PI Option allows two PIs, termed Initiating and Partnering PIs, to collaborate on a single application.
    • ·         When submitting the pre-application it is the responsibility of the applicant to select the funding level that is most appropriate for the research proposed.  The funding level should be selected based on the scope of the research project, rather than the amount of the budget.
    • ·         Clinical trials are allowed.
    • ·         There are no limitations on the number of applications for which an investigator may be named as a Partnering PI.  However, submission of applications with the same Partnering PI on multiple applications is discouraged unless they are clearly unique, meaningful collaborations addressing distinct research questions.
    • ·         Applications must include two or more breast cancer advocates on their research team.
    • ·         Submission of a preproposal is required; application submission is by invitation only.
    • ·         Funding Level 3:
    • ·         Maximum funding of $2.5M in direct costs (plus indirect costs)
    • ·         Maximum period of performance is 4 years
    • ·         Funding Level 3 – Partnering PI Option:
    • ·         Maximum funding of $4M for direct costs (plus indirect costs)
    • ·         Maximum period of performance is 4 years
    • ·         Funding Level 4 and Funding Level 4 – Partnering PI Option:
    • ·         Maximum funding of $10M for direct costs (plus indirect costs)
    • ·         Maximum period of performance is 4 years

     

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism is also found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

     

    Applications must be submitted through the federal government’s single-entry portal, Grants.gov.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the BCRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

     

    Point of Contact:

    CDMRP Help Desk
    301-682-5507
    help@eBrap.org


  • 16 Jul 2018 2:01 PM | Hawk Tran (Administrator)

    The FY18 Defense Appropriation provides $125 million (M) to the Department of Defense Psychological Health and Traumatic Brain Injury Research Program (PHTBIRP) to support specific Defense Health Agency (DHA) J9 Directorate research program areas, including Joint Program Committee-5/Military Operational Medicine Research Program (JPC-5/MOMRP).  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the DHA J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcement/Funding Opportunity is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

    The PH/TBIRP and JPC-5/MOMRP are providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY18 PHTBIRP Program Announcement and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in August 2018.  Pre-application and application deadlines will be available when the Program Announcement is released.  This pre-announcement should not be construed as an obligation by the government.

    http://cdmrp.army.mil/pubs/press/2018/18phtbipreann_r2oe

    Resiliency and Readiness Optimization/ Enhancement (R2OE)Translational Research Award

    Intramural (DoD) and extramural investigators at all academic levels (or equivalent) are eligible to submit applications

    Proposals/applications to the FY18 PHTBIRP R2OE Translational Research award should support research with the goal of evaluating evidence-based interventions and techniques to optimize and enhance resilience and psychological health readiness of Service members (SM).  The expectation of this research is to demonstrate the utility of these resiliency and readiness enhancement interventions and techniques to benefit our SMs and the public at large.

    ·      The maximum period of performance is 3 years.

    The maximum allowable total costs per award (direct and indirect) for the entire period of performance is $3M

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the PHTBIRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 16 Jul 2018 1:48 PM | Hawk Tran (Administrator)

    The FY18 Defense Appropriation provides $21 million (M) to the Department of Defense Gulf War Illness Research Program (GWIRP) to support high-impact research that will identify effective treatments and accelerate their clinical application, identify objective markers for improved definition and diagnosis, and/or provide a better understanding of the pathobiology underlying the complex of Gulf War Illness symptoms. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

    The GWIRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications. FY18 PRCRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in August 2018. Pre-application and application deadlines will be available when the Program Announcement is released. This pre-announcement should not be construed as an obligation by the government.

    http://cdmrp.army.mil/pubs/press/2018/18gwirppreann_nia

    The following mechanism is planned for release:

    New Investigator Award

    • PIs may apply under one of the following three eligibility categories:
    • Transitioning Postdoctoral Fellow: Senior postdoctoral fellows who have completed at least 3 years of postdoctoral training.
    • Early-Career Investigator: Independent investigators within 5 years since their last training position.
    • Submission of a Letter of Intent is required.
    • Encourages applications from early stage and established investigators new to the field of GWI research.
    • Previous experience in GWI research is not required; however, collaborations with experienced GWI researchers are encouraged.
    • Preliminary data are not required, and if provided, do not necessarily have to come from the GWI research field.
    • Studies that provide outcomes clearly translatable to clinical use are encouraged.
    • Clinical trials are not allowed.
    • Submission of a Letter of Intent is required.· New GWI Researcher: Established independent investigators who have received less than $300,000 in federally funded, non-mentored GWI research.
    • The maximum allowable funding for the entire period of performance is $500,000 for direct costs.
    • The maximum period of performance is 3 years.
    • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Applications must be submitted through the federal government’s single-entry portal, Grants.gov.  Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the GWIRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 13 Jul 2018 8:53 AM | Hawk Tran (Administrator)

    The FY18 Defense Appropriation provides $12 million (M) to the Department of Defense Reconstructive Transplant Research Program (RTRP) to support research projects that specifically address needs in the field of vascularized composite allotransplantation (VCA).  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

    FY18 RTRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website. 

    Focus Areas:  The FY18 RTRP encourages research projects that specifically address needs in the field of vascularized composite allotransplantation (VCA) in the following focus areas:

    • ·        Reduce the risks of VCA-associated immunotherapy
    • ·        Revolutionize ex vivo VCA tissue preservation strategies to extend the timeline between procurement and transplantation
    • ·        Identify near- and long-term functional, quality-of-life, and psychosocial outcomes in VCA

    http://cdmrp.army.mil/funding/rtrp

    Concept Award (CA) – Letter of Intent due 10/3/18

    Investigators at or above the level of postdoctoral fellow (or equivalent)

    • Pre-application (Letter of Intent) is required.
    • Supports the exploration of a highly innovative new concept or untested theory that addresses an important problem relevant to reconstructive transplant. 
    • Preliminary data are NOT allowed.
    • Reviewers at both tiers of review will be blinded to the identity of the Principal Investigator (PI), collaborators, and their organizations.
    • Applications must address at least one of the FY18 RTRP Focus Areas.

    ·      Maximum funding of $200,000 for total costs (direct plus indirect costs)

    • ·      Maximum period of performance is 18 months

    Investigator-Initiated Research Award (IIRA) – Preproposal due 8/15/18

    Independent investigators at all academic levels (or equivalent)

    • Preproposal is required; full application submission is by invitation only.
    • Supports studies with potential to make an important contribution to the reconstructive transplant research field, patient care, and/or quality of life.
    • Preliminary or published data required.
    • Multiple PI Option supports synergistic partnerships among two to four investigators collaborating on a single application; multi-institutional collaborations are encouraged.
    • Applications must address at least one of the FY18 RTRP Focus Areas.

    Individual PIs:

    ·      Maximum funding of $1 million (M) for total costs

    ·      Maximum period of performance is 3 years

    Multiple PI Option:

    ·      Maximum funding of $1.5M for total costs

    • ·      Maximum period of performance is 3 years

    Qualitative Research Award (QRA) – Preproposal due 8/15/18

    Independent investigators at all academic levels (or equivalent)

    • Preproposal is required; full application submission is by invitation only.
    • Supports qualitative research studies that will help researchers and clinicians to better understand the experiences of individuals who are considering, or have already received, reconstructive transplant surgery.
    • Demonstrated qualitative research experience within the research team is required.
    • Applications must address the following FY18 RTRP Focus Area:

           Identify near- and long-term functional, quality-of-life, and psychosocial outcomes in VCA

    Multiple PI Option supports synergistic partnerships among two to four investigators collaborating on a single application; multi-institutional collaborations are encouraged.

    ·      Maximum funding of $1M for total costs

    ·      Maximum period of performance is 3 years

    Multiple PI Option:

    ·      Maximum funding of $1.5M for total costs

    • ·      Maximum period of performance is 3 years.

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the RTRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Help Desk

    301-682-5507
    help@eBrap.org


  • 10 Jul 2018 2:12 PM | Hawk Tran (Administrator)

    NAVREF was recently recognized for our transparency with a 2018 Gold Seal on our GuideStar Nonprofit Profile!

    GuideStar is the world’s largest source of information on nonprofit organizations. More than 8 million visitors per year and a network of 200+ partners use GuideStar data to grow support for nonprofits.

    In order to get the 2018 Gold Seal, NAVREF shared important information with the public using our profile on www.guidestar.org. Now our community members and potential donors can find in-depth information about our goals, strategies, capabilities, and progress. We’re shining a spotlight on the difference we help make in the world. 

    Don't believe us? Check out our profile on GuideStar or look at our logo at the footer of our website. 


  • 2 Jul 2018 1:52 PM | Hawk Tran (Administrator)

    The FY18 AIMM Program Announcement and General Application Instructions for the following award mechanism are anticipated to be posted on Grants.gov in August 2018.  Pre-application and application deadlines will be available when the Program Announcement is released.  This pre-announcement should not be construed as an obligation by the Government, and funding of research projects received in response to the Program Announcement is contingent on the availability of Federal funds.

    As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) Research and Development Directorate (J9) manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

    http://cdmrp.army.mil/pubs/press/2018/18dmrdp-aimmpreann

    AIMM Research Award

    • Independent investigators at all academic levels (or equivalent)
    • Supports highly creative and conceptually innovative high-risk research with the potential to accelerate critical discoveries or major advancements that will significantly impact military health and medicine
    • Supports novel research concepts and development of enabling technologies; not intended to support incremental advances on previous or ongoing work
    • Supports applied research efforts that initiate or enhance potential game-changers; clinical trials are not allowed.

    ·         Projects proposed should be relevant to at least one DoD medical research program area.  Cross-cutting research projects with the potential to benefit multiple DoD medical research program areas are highly encouraged. 

    ·         Applications using synthetic or systems biology-based approaches are highly encouraged

    • ·         Preliminary data that are relevant to the proposed research are encouraged, but not required.
    • Preproposal is required; application submission is by invitation only

    ·         Maximum funding of $350,000 for direct costs (plus indirect costs)

    • Maximum period of performance is 18 months

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcement and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all USAMRMC funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

     

    Applications must be submitted through the federal government’s single-entry portal, Grants.gov.  Submission deadlines are not available until the Program Announcement is released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 20 Jun 2018 3:10 PM | Hawk Tran (Administrator)

    The FY18 Defense Appropriations Act provides $100 million (M) to the Department of Defense Prostate Cancer Research Program (PCRP) to support innovative, high-impact prostate cancer research. As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, Research, Development, and Acquisition (DHA RDA) Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

     

    FY18 PCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on Grants.gov. 

     

    The mission of the PCRP is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of Service members, Veterans, and all men experiencing the impact of the disease.  Applications submitted to the FY18 PCRP must addresses one or more of the Overarching Challenges (revised for FY18):

    ·         Develop treatments that improve outcomes for men with lethal prostate cancer

    ·         Reduce lethal prostate cancer in African Americans, Veterans, and other high-risk populations

    ·         Define the biology of lethal prostate cancer to reduce death

    ·         Improve the quality of life for survivors of prostate cancer

     

    http://cdmrp.army.mil/funding/pcrp

     

    Health Disparity Research Award – Letter of Intent due September 20, 2018

    • Established Investigators:  Independent investigators at or above the level of Assistant Professor (or equivalent)
    • Or New Investigators:  Investigators that meet the following criteria at the application submission deadline date:

    ·         Have the freedom to pursue individual aims without formal mentorship

    ·         Have not previously received a PCRP Health Disparity Research Award and/or Idea Development Award

    • Have completed at least 3 years of postdoctoral training or fellowship and are within 10 years after completion of a terminal degree (excluding residency or family medical leave)

    ·         Supports new ideas for prostate cancer research that have the potential to make an important contribution to reducing and ultimately eliminating disparities in prostate cancer incidence, morbidity, and mortality. 

    ·         Research ideas should be innovative, but primary emphasis will be placed on the potential impact of the proposed work.

    ·         Preliminary data are encouraged, but not required.

    • Proposed projects may include basic, translational, or clinical research, including clinical trials.
    • Must address at least one of the FY18 PCRP Overarching Challenges.
    • New Investigator Option supports applicants early in their faculty appointments or in the process of developing independent research careers.

    ·         Established Investigators:

    ·         Maximum funding of $1,000,000 for direct costs (plus indirect costs).

    ·         New Investigators:

    ·         Maximum funding of $600,000 for direct costs (plus indirect costs).

    • Maximum period of performance is 3 years.

     

     

    Health Disparity Scholar Award – Letter of Intent due bu September 20, 2018

    By March 31, 2019

    Postdoctoral Ph.D. or M.D. PIs:

    • Must have successfully defended a doctoral thesis or possess an M.D. degree
    • Have 3 years or less of postdoctoral research experience

    ·         Supports research opportunities focused on reducing and ultimately eliminating disparities in prostate cancer incidence, morbidity, and mortality for individuals in the early stages of their careers.

    • PIs must have a designated mentor who is an experienced prostate cancer researcher.
    • Must address at least one of the FY18 PCRP Overarching Challenges.

    ·         Maximum funding of $200K for direct costs (plus indirect costs).

    • Maximum period of performance is 2 years.

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

     

    Applications must be submitted through the Federal Government’s single-entry portal, Grants.govFor email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the PCRP or other CDMRP-administered programs, please visit the CDMRP website.

    Point of Contact:

    CDMRP Help Desk

    301-682-5507
    help@eBrap.org


  • 20 Jun 2018 3:10 PM | Hawk Tran (Administrator)

    FY18 PRORP Program Announcements and General Application Instructions for the following award mechanisms are posted on Grants.gov. 

    As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate, manages the Defense Health Program Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP).

    The mission of the PRORP is to address the most significant gaps in care for the leading burden of injury for facilitating return-to-duty by funding innovative, high-impact, clinically relevant research to advance optimal treatment and rehabilitation from musculoskeletal injuries sustained during combat and combat-related activities. 

    Prolonged Field Care (PFC) has been identified as the number one capability gap across the Army.  PFC includes field trauma care extended beyond doctrinal timelines until the patient can be transported from the point of injury to an appropriate level of care.  In order to address this gap and prepare the orthopaedic field for the next conflict or mass event, the FY18 PRORP has identified several orthopaedic areas of focus for funding that will support patient care closer to the point of injury and to allow patients to more quickly return to duty/work. 

    The PRORP will solicit research applications that specifically address at least one of the following FY18 Focus Areas:

    • o   Animal Models - Develop animal models that replicate Prolonged Field Care-related injuries, including ischemia reperfusion injury and compartment syndrome.
    • o   Device Development - Develop offloading and stability devices (e.g., braces, casting) for ligamentous injuries, small extremity fractures, and /or other non-severe common battlefield musculoskeletal injuries for immediate return to duty.
    • o   Wound Infection – Evaluate and /or translate promising available clinical interventions in prevention and control of combat extremity wound infections (e.g., for long bone open fractures) to improve their durability to treat Service member injuries as close as possible to the point of injury.  Projects that further develop novel wound protectants for this population will also be considered.
    • o   Treatment Techniques and Outcomes - Develop and /or evaluate optimal non-surgical and /or surgical treatment strategies and intervention delivery parameters (e.g., frequency, intensity, time, and intervention type) to rapidly remediate duty-limiting  impairments, functional limitations, or barriers to full duty readiness following orthopedic injuries.  Interventions may include, but are not limited to:  combination therapies (simultaneous application of multiple treatment modalities), injections, dry needling, manual therapy, therapeutic exercise, or other techniques to return Service members to duty within 72 hours.
    • o   Surgical Care - Translate early research findings, in any of the below Surgical Care Areas, to humans.
    • §  Surgical Care Areas: Peripheral Nerve Injuries, Prevention of Heterotopic Ossification, Volumetric Muscle Loss, Extremity Fractures, Pelvic Ring Injuries, Compartment Syndrome, Gaps in Clinical Practice Guidelines (http://www.usaisr.amedd.army.mil/cpgs.html), Surgical Techniques to Optimize Gait, Soft Tissue Trauma, Osteoarthritis
    • o   Surgical Techniques and Outcomes - Evaluate optimal surgical treatment strategies, tools, and delivery parameters to improve functional outcomes of Service members who have sustained orthopaedic injuries.  The proposed research should address at least one topic from the Surgical Care Areas (listed below), and strategies to return the patient to duty and potentially shorten recovery in theater.
    • §  Surgical Care Areas: Peripheral Nerve Injuries, Prevention of Heterotopic Ossification, Volumetric Muscle Loss, Extremity Fractures, Pelvic Ring Injuries, Compartment Syndrome, Gaps in Clinical Practice Guidelines (http://www.usaisr.amedd.army.mil/cpgs.html), Surgical Techniques to Optimize Gait, Soft Tissue Trauma, Osteoarthritis
    • o   Rehabilitation Techniques and Outcomes – Evaluate optimal rehabilitation treatment strategies, tools, and delivery parameters to improve functional outcomes for immediate return to duty of Service members who have sustained orthopaedic injuries. 
    • o   Acute Pain - Evaluate promising available or emerging clinical interventions to control acute pain (e.g., analgesics, anti-inflammatory agents, nerve blocks) following orthopaedic injuries in the pre-hospital setting.  Projects that investigate a pathway to enhance non-physician capabilities to deliver rapid, long lasting, analgesia with minimal cognitive side effects in an austere environment are encouraged.
    • o   Improved Surgical Interventions - Develop or optimize orthopaedic surgical interventions to support their use in the pre-hospital environment.
    • o   Tissue Regeneration:
    • §  Development and preclinical testing of therapies for volumetric muscle loss due to traumatically damaged tissues of the extremities. 
    • §  Develop and /or evaluate regenerative medicine therapies (devices, drugs, biologics, and /or techniques) for traumatically injured tissues of the extremities.
    • §  Evaluate advanced regenerative medicine therapeutics for restoration of traumatically injured extremity tissues.

    The following FY18 PRORP award mechanisms are released (note that Focus Area requirements vary by award mechanism):

    http://cdmrp.army.mil/funding/prorp

    Applied Research Award – Preproposal due July 30, 2018

    • Independent investigators at all academic levels (or equivalent) are eligible to submit applications.
    • Pre-application is required; full application submission is by invitation only.
    • Supports applied research applications focused on advancing optimal treatment and restoration of function for military personnel with musculoskeletal injuries sustained during combat or combat-related activities.
    • Proposed research should be supported by preliminary data and have the potential to make significant advancements toward clinical translation.
    • Clinical trials are not allowed under this award mechanism.
    • Applications must address one the following FY18 PRORP Focus Areas:
      • Animal Models
      • Device Development
      • Wound Infection
      • Tissue Regeneration
    • Maximum funding of $750,000 for total costs.
    • Maximum period of performance is 3 years.

    Clinical Trial Award – Preproposal due July 30, 2018

    • Independent investigators at all academic levels (or equivalent) are eligible to submit applications.
    • Pre-application is required; full application submission is by invitation only.
    • Supports rapid implementation of clinical trials with the potential to have a major impact on military combat-related orthopaedic injuries, or non-battle injuries that significantly impact unit readiness and return-to-duty/work rates.
    • Funding must support a clinical trial and may not be used for preclinical research studies.
    • Collaboration with military researchers and clinicians is encouraged.
    • Studies that include active duty military or Veteran participants as all or a portion of the study population will be considered.
    • Investigational New Drug or Investigational Device Exemption applications, if needed, should be submitted to the Food and Drug Administration within 6 months of the award date.
    • Applications must address one the following FY18 PRORP Focus Areas:
      • Surgical Techniques and Outcomes
      • Rehabilitation Techniques and Outcomes
      • Acute Pain
      • Improved Surgical Interventions
      • Tissue Regeneration
    • Maximum funding of $3 million (M) for direct costs (plus indirect costs).
    • Maximum period of performance is 4 years.

    Clinical Translational Research Award – Preproposal due July 30, 2018

    • ·        Independent investigators at all academic levels (or equivalent) are eligible to submit applications.
    • ·        Pre-application is required; full application submission is by invitation only.
    • ·        Supports high-impact and/or emerging research that may or may not be ready for a full scale randomized controlled clinical trial.
    • ·        Funding must support clinical research studies involving humans.
    • ·        Preliminary or published data relevant to the proposed research project are required.
    • ·        Collaboration with military researchers and clinicians is encouraged.
    • ·        Studies that include active duty military or Veteran participants as all or a portion of the study population will be considered.
    • ·       Investigational New Drug or Investigational Device Exemption applications, if needed, should be submitted to the Food and Drug Administration within 6 months of the award date.
    • ·        Applications must address one the following FY18 PRORP Focus Areas:
    • Treatment Techniques and Outcomes
    • Wound Infection
    • Surgical Care
    • Tissue Regeneration

    ·        Maximum funding of $2M for direct costs (plus indirect costs),

    ·        Maximum period of performance is 4 years.

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Applications must be submitted through the Federal Government’s single-entry portal, Grants.gov.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the PRORP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Help Desk
    301-682-5507
    help@eBrap.org


  • 20 Jun 2018 3:09 PM | Hawk Tran (Administrator)

    The FY18 Defense Appropriation provides $10 million (M) to the Department of Defense Orthotics and Prosthetics Outcomes Research Program (OPORP) to support research that evaluates the comparative effectiveness of orthotic and prosthetic clinical interventions using patient-centric outcomes for Service members and Veterans who have undergone limb amputation.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate, manages the Defense Health Program Research, Development, Test, and Evaluation appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

    FY18 OPORP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov. 

    OPORP awards are focused on outcomes-based best practices through analysis of the merits of prosthetic and orthotic device options currently available, not on the development of new or the improvement of existing technology.  The intent of the awards is to generate clinically useful evidence that will enhance and optimize patient outcomes.

    Focus Areas:  The OPORP will only consider applications that specifically address the critical needs of the Orthotics and Prosthetics Outcomes research community in one or more of the FY18 Focus Areas.  The OPORP will solicit research applications that address at least one of the following FY18 Focus Areas:

    • Orthotic or Prosthetic Device Form:  Understand patient outcomes through the analysis and characterization of variables related to the form of currently available clinical options such as device size, shape, material, and/or configurations.
    • Orthotic or Prosthetic Device Fit:  Understand patient outcomes related to human-device interface and component connection through the analysis of variables in currently available clinical options that facilitate fit-related metrics such as comfort and/or usability.
    • Orthotic or Prosthetic Device Function:  Understand patient outcomes through the analysis of variables related to currently available device function such as device control, sensors, and passive or active response with respect to activities of daily living and other real-world activities.

    http://cdmrp.army.mil/funding/oporp

     

    Clinical Research Award – Preproposal due August 6, 2018

    • Independent investigators at all academic levels (or equivalent)
    • Supports research that evaluates the comparative effectiveness of orthotic and/or prosthetic clinical interventions using patient-centric outcomes for Service members and Veterans with limb loss and/or limb impairment.
    • Proposed projects should be designed to provide outcomes data regarding orthotic and/or prosthetic devices and must include the anticipated effect on patient care metrics.
    • Collaboration among academia, industry, the DoD, and the Department of Veterans Affairs (VA) is highly encouraged, including longitudinal outcomes studies.
    • Applications submitted to the FY18 OPORP CRA must address one or more of the FY18 OPORP Focus Areas.
    • Animal studies are not allowed.
    • Clinical trials are not allowed.
    • Preproposal submission is required; application submission is by invitation only.

    ·         Funding Level 1:

    o   Maximum funding of $350,000 for total costs (direct costs plus indirect costs)

    o   Maximum period of performance is years.

    ·         Funding Level 2:

    o   Maximum funding of $1,500,000 for total costs (direct costs plus indirect costs)

    • Maximum period of performance is years.

     

    Clinical Trial Award – Preproposal due August 6, 2018

    Independent investigators at all academic levels (or equivalent)

    ·         Supports rapid implementation of clinical trials with the potential to make significant impacts on improving health and well-being of Service members and Veterans with limb loss and/or limb deficit.

    ·         Supports research that evaluates the comparative effectiveness of orthotic and/or prosthetic clinical interventions using patient-centric outcomes.

    ·         Proposed projects should be designed to provide outcomes data regarding orthotic and/or prosthetic devices and must include the anticipated effect on patient care metrics.

    ·         Collaboration among academia, industry, the DoD, and the VA is highly encouraged, including longitudinal outcomes studies.

    ·         Applications submitted to the FY18 OPORP CTA must address one or more of the FY18 OPORP Focus Areas.

    ·         Preclinical research is not allowed.

    ·         Preproposal submission is required; application submission is by invitation only.

    • Preclinical research is not allowed.

    ·         Funding Level 1:

    o   Maximum funding of $350,000 for total costs (direct costs plus indirect costs)

    o   Maximum period of performance is years.

    ·         Funding Level 2:

    o   Maximum funding of $2,500,000 for total costs (direct costs plus indirect costs)

    • Maximum period of performance is years.

     

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

     

    For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the OPORP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Help Desk
    301-682-5507
    help@eBrap.org


  • 12 Jun 2018 11:54 AM | Hawk Tran (Administrator)

    The FY18 Defense Appropriation provides $5 million (M) to the Department of Defense Lupus Research Program (LRP) to support innovative and impactful research that addresses fundamental issues in lupus.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

    FY18 LRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website. 

    Applications submitted to the FY18 LRP must address at least one of the three Focus Areas listed below:

    •           Understand lupus disease heterogeneity including, but not limited to, progressive stages of lupus disease over time, strategies and technologies to subtype patients, lupus disease mechanisms, biopsychosocial studies, personalized medicine, variation in treatment and its effects on patient outcomes, socioeconomic studies, environmental studies, and epidemiological studies.

    •           Understand how the underlying genetic components and gene environment interactions of lupus disease relate to clinical disease characteristics using functional genomic studies.

    •           Determine the pathobiology of lupus in target human tissues including, but not limited to, imaging studies, genomics of lupus disease in particular tissues, and metabolomics and how understanding the underlying pathobiology will improve quality of life of patients.

    http://cdmrp.army.mil/funding/lrp

     

    Concept Award – Letter of Intent due October 10, 2018

    Investigators at all academic levels

    ·         Supports highly innovative, untested, potentially groundbreaking concepts in lupus research

    ·         Emphasis is on innovation

    ·         Clinical trials are not allowed

    • Preliminary data is not required

    ·         Maximum funding of $150,000 for total costs

    • Maximum period of performance is year

     

    Impact Award – Letter of Intent due October 10, 2018

    Investigators at or above Assistant Professor (or equivalent)

    ·         Supports innovative, high-risk/high-reward research

    ·         Emphasis is on impact

    ·         Clinical trials are not allowed

    • Preliminary data is encouraged but not required

    ·         Maximum funding of $525,000 for total costs

    • Maximum period of performance is 3 years

     

    A pre-application (Letter of Intent) is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

     

    For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the LRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

    Point of Contact:

    CDMRP Help Desk
    301-682-5507
    help@eBrap.org


<< First  < Prev   1   2   3   4   5   ...   Next >  Last >> 

1717 K ST NW Suite 900

Washington, DC 20006

P: 301-656-5005  |  admin@navref.org

Powered by Wild Apricot Membership Software